Protein tyrosine phosphorylation as a mechanism which regulates cytokine activation of early response genes  by Larner, Andrew C. & Finbloom, David S.
ELSEVIER Biochimica et Biophysica Acta 1266 (1995) 278-287 
BB Biochi~ic~a 
et Biophysica ~ta 
Mini-Review 
Protein tyrosine phosphorylation as a mechanism which regulates 
cytokine activation of early response genes 
Andrew C. Lamer *, David S. Finbloom 
Division of Cytokine Biology, Center for Biologics Evaluation and Research, 8800 Rockville Pike, Bethesda, MD 20892, USA 
Received 11 August 1994; revised 28 December 1994; accepted 25 January 1995 
Abstract 
Two well-defined rapid responses which occur as a consequence of growth factors binding to their cell surface receptors involve 
tyrosine phosphorylation f cellular proteins and the induction of the transcription of cellular genes. Recent advances have been made in 
purification and cloning of Src homology 2 and 3 (SH2/SH3) domain-containing transcription factors which are required for the 
activation of early response genes by interferons. These transcription factors are covalently modified by tyrosine phosphorylation such 
that they interact with enhancers needed for interferon-stimulated g ne expression. The Jak family of tyrosine kinases are also an integral 
component in these signalling cascades. The information gained concerning interferon signalling has now been extended to include a 
broad network of cytokine-regulated signalling systems which use tyrosine phosphorylation f a family of structurally related proteins to 
activate transcription of early response genes. 
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1. Introduction 
Expression of early response genes as a result of the 
interaction of growth factors and cytokines with specific 
cell surface receptors allows cells to respond rapidly to 
changes in their environment. In some cases, such as TNF 
induction of the interleukin-1 gene, the signalling pathway 
from the membrane to the nucleus requires the activation 
of the transcription factor NFK B. In other cases, such as 
antigen-stimulation of interleukin-2 gene transcription, the 
transcription factor NF-AT is required [1,2]. However, the 
mechanisms by which many other cytokines and growth 
factors rapidly induce the transcription of cellular genes 
have until recently remaiined unclear. Elucidation of the 
interferon signalling cascade provides insight into the 
mechanisms by which several other cytokines might also 
regulate gene expression. 
This review will address advances in our understanding 
of the mechanisms by which interferons activate the ex- 
pression of early response genes through tyrosine phospho- 
rylation of a newly defined family of transcription factors 
termed signal transducers; and activators of transcription 
(Stat) [3]. The information gained from studies of inter- 
feron-activated gene expression will be discussed in the 
context of other cytokines which appear to use some of the 
same or similar mechanisms tostimulate tyrosine phospho- 
rylation of Stat proteins. 
presence of actinomycin D, an inhibitor of RNA synthesis 
[4-9]. Isolation of both cDNAs corresponding to these 
proteins and other IFN-induced RNAs confirmed that 
unique sets of cellular genes were transcriptionally acti- 
vated by treatment of cells with either IFNa/fl (type I) 
and/or IFNT (type II) [10,11]. Isolation of the promoters 
of several IFNa/fl-stimulated genes permitted the map- 
ping of an enhancer termed the interferon-stimulated r - 
sponse element (ISRE) which was demonstrated to be 
necessary and sufficient for activation of these genes 
[ 12,13]. Likewise, a distinct consensus element was mapped 
in the promoters of genes that are activated by IFNy. This 
element has been given a variety of acronyms including 
gamma response region (GRR) and IFNy activation se- 
quence (GAS) [14,15]. Depending upon the GRR sequence 
used, the origin of the cell extract and the cytokine with 
which a cell is treated, one or several complexes have been 
observed to bind to these sequences using electrophoretic 
mobility shift assays (EMSA) [16-18]. The implications of 
this finding will be discussed in section 6. Alignments of 
the sequences required for activation of several inducible 
genes by either IFNcz/fl or IFNT are shown in Table 1. 
3. Characterization of the transcription factors which 
interact with the ISRE 
2. Enhancers in the promoters of IFN-stimulated genes 
Incubation of cells with interferons induces the biosyn- 
thesis of several new proteins, which are inhibited in the 
Table 1 
Representative ISRE, GAS and GRR sequences that have been shown to 
be required for either IFNot (ISRE) or IFNy (GAS/GRR)-stimulated 
gene expression 
Gene Enhancer element 
ISRE 
ISG54 TAG TTT CAC TrT CCC 
ISG15 CAG TTT CGG ' ITr  CCC 
6-16 GAG T IT  CAT T IT  CCC 
H-2L CAG TTT CCC TTT CAG 
Gas-like 
GBP TTAC TCT AA 
MIG TTAC TAT AA 
GRR-like 
Fcgrl TTCC CAG AA 
LY-6E TTCC TGT AA 
ICSBP TTCC GAG AA 
IRF1 TTCC CCG AA 
a 2-MG TTCT GGG AA 
Enhancer elements used in cytokine/growth factor induced genes. Al- 
though many cytokine activated Stat containing DNA-hinding complexes 
bind to both GAS and GRR-like sequences, others electively bind to one 
or the other element. Therefore we have grouped enhancers into those 
which contain either GAS or GRR sequences. 
Definition of an ISRE in the promoters of several 
responsive genes allowed the characterization of three 
distinct protein complexes, termed interferon-stimulated 
gene factors (ISGF1, ISGF2 and ISGF3), that interact with 
this enhancer as assayed by EMSAs [ 19,20]. Two of these 
complexes (ISGF1 and ISGF2) are present in nuclear 
extracts prepared from untreated cells, while a third com- 
plex of slower mobility called ISGF3 or E factor is ob- 
served only in extracts prepared from cells incubated with 
IFNa/fl [19,20]. The ISGF1 complex contains the inter- 
feron regulatory factor 2 (IRF-2) protein [21] originally 
cloned and characterized by the laboratory of Taniguchi as 
a transcription factor which represses transcription of the 
IFNfl gene (unpublished observations). The ISGF2 com- 
plex contains the interferon regulatory factor (IRF-1) pro- 
tein which had been implicated as a positive activator of 
IFNfl gene expression [22,23]. Although the amount of 
ISGF2 binding to the ISRE is increased upon treatment of 
cells with either IFNot/fl or IFNy, this increase requires 
protein synthesis and was thus hypothesized not to be the 
primary signal required for the activation of cellular genes 
by IFNa/fl [19]. IFNot/fl-stimulated binding of ISGF3 or 
E factor to the ISRE displayed several properties which 
indicated that the formation of this complex was the 
primary signal required for activation of immediate arly 
genes. Formation of ISGF3 could be detected within min- 
utes after stimulation of cells with interferon, its assembly 
occurred in the absence of protein synthesis, and the 
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complex itself was shown to translocate from the cyto- 
plasm to the nucleus [19,20]. Furthermore, mutations in the 
ISRE sequence demonstrated a direct correlation between 
formation of ISGF3 and induction of IFN-induced gene 
expression [24,25]. 
Purification of the ISGF3 revealed that it contained four 
polypeptides. ISGF3y has a molecular size of 48kDa, and 
ISGF3a consists of three proteins of 84kDa, 91kDa and 
113kDa [26]. cDNA clones corresponding to all four pro- 
teins have been obtained [27-29]. ISGF3y directly binds 
to the ISRE in the absence of IFN treatment of cells, and is 
a member of the interferon regulatory factor family of 
transcription factors which include IRF-I, IRF-2 and 
ICSBP, all of which also bind to ISREs [29]. The DNA 
binding domain of ISGF3y has been mapped to the N- 
terminal 125 amino acids, while another domain of 160 
amino acids located at the carboxy terminus of the protein 
is required for interaction with the ISGF3 a proteins [30]. 
Sequencing of the 84, 91 and 113kDa proteins indicated 
that p84 and p91 were identical except for an additional 38 
amino acids present at the carboxy terminus of p91 [27]. 
Although the 113kDa protein was different from p91, there 
were significant regions of homology [28,31]. Both pro- 
teins contained SH2 and SH3 domains and a highly nega- 
tively charged region in their carboxy terminus [28,31]. 
Significant homology is also present in their amino termi- 
nal ends which contain three predicted helices [31]. Al- 
though it is clear that the SH2 domains of p91 and p113 
permit these proteins to assembly into complexes which 
bind to the ISRE, the function of these other regions of 
homology remains to be defined. 
4. Characterization of the proteins that interact with 
the GRR / GAS sequence 
It has long been known that IFNT induces genes such 
as HLA class II, but this requires extended periods of time 
(24 h) and protein synthesis. However, there are a few 
genes whose promoters were well characterized and whose 
expression was rapidly enhanced after exposure to IFNy 
[15,33-36]. One such gene was the guanlylate binding 
protein [35]. The promoter region of this gene contains an 
element referred to as the gamma activation sequence 
(GAS). GAS is necessary and sufficient for activation of 
this gene by IFNy [14]. The proteins binding to this 
sequence were initially characterized by exonuclease III 
assays but later were identified by EMSA [37,38]. The 
proteins binding to GAS were referred to as gamma ctiva- 
tion factors (GAF) and were shown to be rapidly induced 
following exposure of cells to IFNy. Another gene found 
to be rapidly transcriptionally activated by IFNy is the 
high affinity Fcy receptor gene (FcyR1). The promoter of 
FcyR1 was shown to contain an enhancer that was neces- 
sary and sufficient for the induction of reporter-promoter 
constructs by IFN'y [15]. This sequence was referred to as 
the gamma response region (GRR). Treatment of cells with 
IFNy resulted in the rapid induction of factors that specifi- 
cally bind to this element [17]. Although the GAS and 
GRR elements are similar and part of a larger group of 
related elements, IFNy induced factors that bound to the 
GRR were not always competitively inhibited by the GAS 
element, suggesting that there are differences in the recog- 
nition of these elements by activated transcription factor 
complexes [18,39]. 
Purification and cloning of the ISGF3 proteins permit- 
ted the development of antibodies, and it became possible 
to determine whether other IFN-induced DNA binding 
protein complexes contained these proteins. Using antibod- 
ies specific for the p91 protein, it became vident hat the 
IFNy-activated factors that bound to the GAS and GRR 
elements contained this protein [16,40,41]. However, there 
was no evidence for the presence of p113 in any of the 
IFNy activated DNA binding complexes. Further work 
demonstrated that these proteins bind as dimers and that 
both homo- and heterodimers can exist [42]. 
5. IFN activation of the Slat proteins 
Previous reports suggested that a protein kinase, possi- 
bly protein kinase C might be involved in the activation of 
IFN-induced ISRE binding proteins [43,44]. These conclu- 
sions were based upon the fact that protein kinase in- 
hibitors prevented ISGF3 formation, and that ATP was 
required for in vitro activation of ISGF3 in cell ho- 
mogenates [45-48]. With the development of specific anti- 
serum against p91/84 and pl13 it became evident that 
these transcription factors were tyrosine phosphorylated in 
response to treatment of cells with IFN~, whereas only 
p91 was tyrosine phosphory lated by IFN y 
[27,31,37,40,41,57]. Phosphopeptide mapping showed that 
IFNy and IFNa induced tyrosine phosphorylation f p91 
at tyrosine 701 and that a tyrosine adjacent to a relatively 
similar sequence in p113 (Y-690) was phosphorylated by
IFNa [49,50]. Two other experimental pproaches pro- 
vided further information regarding the components re- 
quired for IFN activation of the Stat proteins. One ap- 
proach involved the selection of cell lines which were 
defective in either I FNa/ f l  or IFNy signalling, and recon- 
stitution of IFN signalling in these lines with cDNAs 
corresponding to the defective proteins (for review see 
Ref. [3]). The other approach was the development of a 
cell-free system where it was possible to activate the 
formation of ISGF3 and IFNy-induced DNA-binding com- 
plexes using either cell homogenates or partially purified 
plasma membranes [37,41,47,57]. 
The laboratories of Stark and Kerr developed a system 
for selection of cell mutants defective in IFNa signalling, 
some of which were also defective in IFNy signalling 
[51-53]. Analysis of these lines indicated that they could 
be segregated into several complementation groups (see 
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Ref. [3] for review). The initial mutant (U1) defective in 
IFNa signalling was rescued by complementation with the 
protein tyrosine kinase Tyk2 [54]. This observation ot 
only provided evidence for a functional role for Tyk2, but 
also suggested that other tyrosine kinases structurally re- 
lated to Tyk2 (Jakl, Jak2, and Jak3) may function in a 
similar manner. Subsequently, several other mutants have 
been rescued by either the Jakl, Jak2 tyrosine kinases or 
cDNA clones corresponding to the protein components 
which comprise ISGF3 [50,55,56]. Complementation f the 
cell lines has clearly provided important information con- 
cerning which kinases are needed for both IFNa and IFN 3, 
induced gene expression, and will be a very useful system 
to perform structure-function studies to understand in more 
detail what domains are essential within the Jak kinases 
and the Stat proteins for activation by interferons. 
The development of a system that permitted IFNa- 
stimulated formation of ISGF3 in homogenized cells not 
only provided another indication for the role of tyrosine 
kinases in activation of this transcription complex, but also 
suggested that there were several other essential features of 
the activation process [47,57]. Treatment of a plasma 
membrane fraction prepared from HeLa cells with IFNa 
activates the ISGF3a proteins and formation of ISGF3 
when treated membranes were mixed with extracts con- 
taining ISGF37 [47]. This result indicated that the sig- 
nalling cascade is localized to the plasma membrane. 
Interestingly, activation of ISGF3a by IFNa treatment of 
membranes was not sufficient to permit release of the 
tyrosine phosphorylated proteins from the membrane, sug- 
gesting that an independent reaction is required to allow 
the proteins to translocate to the nucleus [47]. The role for 
a tyrosine phosphatase to initiate IFNa-stimulated ISGF3 
formation was inferred from the observation that treatment 
of membranes with the tyrosine phosphatase inhibitor 
vanadate prior to the addition of IFNa inhibited the 
signalling while addition of vanadate to membranes after 
IFNa did not inhibit further formation of the complex [57]. 
Experiments by Igarashi et al. [37] using a cell free system 
to activate the formation of GAF indicated that a tyrosine 
phosphatase aswell as a tyrosine kinase was also required 
for IFN3,-regulated tyrosine phosphorylation of the p91 
protein. 
Using the information obtained from several aborato- 
ries, models by which IFNa and IFN7 stimulate tyrosine 
phosphorylation f the Stat proteins are shown in Figs. 1 
and 2. Activation of transcription complexes by either 
IFNa or IFN3, occurs using plasma membrane-enriched 
110 kDa 
I ISRE I 
Fig. 1. Model of the proteins required for IFNa activation of early response genes. Two components of the IFNa receptor that have been cloned labeled 
IFNaR (100 kDa) [78], and a/f l  [79]. Both of these subunits of the receptor appear to bind human IFNaB2 while the a/f l  subunit binds most species of 
IFNa and IFN/~. Whether there are cooperative interactions between these subunits is not known. It has been postulated that another component of the 
receptor might also be required for signaling. The a/~ subunit has been shown to be constitutively associated with Jakl [79]. Tyk2 is constitutively 
associated with IFNaR subunit of the receptor [82]. Incubation of cells with IFNa induces tyrosine phosphorylation f IFNaR that interacts with Tyk2. 
Tyk2, Jakl p91, 84 and 113 are tyrosine phosphorylated as a result of IFNa treatment of cells. It is not known whether Jakl or Tyk2 directly 
phosphorylates any of the Stat proteins. A protein tyrosine phosphatase appears to be required to initiate signalling, but the substrate(s) with which it 
interacts are not known. Subsequent to activation of the Stat proteins, another reaction is required to release them from the plasma membrane. The nature 
of this reaction has yet to be defined. After translocation to the nucleus, the activated Stats interact with ISGF37 (48 kDa) to form a complex that binds to 
the ISRE and activates the transcription IFNa/fl-stimulated genes. The Stats appear to form dimers, possibly through interactions with their SH2 domains. 
282 A.C. Lamer, D.S. Finbloom / Biochimica et Biophysica Acta 1266 (1995) 278-287 
fractions isolated from a variety of types of cells [37,41,47]. 
Although IFNa activation of ISGF3 requires the ISRE-bi- 
nding protein ISGF3y (which is not tyrosine phospho- 
rylated), whether or not other DNA-binding proteins that 
perform a function similar to ISGF33, exist for those 
complexes which bind to the GRR remains to be clarified. 
UV cross-linking of gel-purified GRR-binding complex 
suggests that a protein of approximately 45kDa is a com- 
ponent of IFNy-stimulated complexes, and at least three 
IFNy-induced complexes bind to the GAS element which 
display differential sensitivities to N-ethyl-maleimide 
[37,41]. In fact, the 48kDa protein has been recently shown 
to be a component of an IFNy-induced complex which 
binds to the GAS element in the GBP promoter [57]. Other 
evidence suggests that p91 might bind directly to the GAS 
element in the GBP promoter [40]. Several reports have 
demonstrated that IFNy-activated complexes which inter- 
act with GRR-like enhancers contain tyrosine phospho- 
rylated p91 [16,40,41,58-62]. Although most if not all 
IFNy-induced transcription complexes that recognize the 
GRR or GAS elements contain p91, there may be other 
p91-related proteins besides p84 that contribute to the 
assembly of these complexes. This is an attractive hypoth- 
esis because it is clear that tyrosine phosphorylated p91 
appears to interact with DNA in the form of a dimer, and it 
would provide for a mechanism of specificity among the 
various cytokines which use these signalling cascades [42]. 
In support of the complementation studies described 
above, biochemical studies from several aboratories have 
confirmed a role for Tyk2 and Jakl in IFNa signalling 
and Jakl and Jak2 in IFNy signalling [63-65]. Each of 
these tyrosine kinases undergoes tyrosine phosphorylation 
in response to ligand binding either as a result of autophos- 
phorylation or as a substrate for an as yet to be identified 
kinase. Since, for instance, most of the src  family kinases 
are regulated by tyrosine dephosphorylation a d phospho- 
rylation, the experiments described above using Hela cell 
membranes are consistent for the role of a tyrosine phos- 
phatase for IFN signalling. It is also interesting to note that 
vanadate, a well-described inhibitor of tyrosine phospha- 
tases, also induces tyrosine phosphorylation of p91 in 
monocytes in the absence of IFN [41]. The cell-specific 
mechanism by which vanadate activates p91 is unclear, but 
may be the result of elevated basal activities of both 
tyrosine kinases and tyrosine phosphatases that are re- 
quired for IFN activation of p91. Although the role of the 
SH2 domain-containing tyrosine phosphatase HCP has 
clearly been documented in erythropoietin signalling [66] 
IFN'yR IFN'yR 
~ " ' ' ' "~  IFNT  
~ZIS~ps~ ~_ \ J Release 
Fig. 2. Model of the proteins required for IFNT activation ofearly response genes. Two proteins that comprise the IFNT receptor have been cloned and 
termed ot and ft. IFN-y binds to the ot component, while the /3 component is species-restricted in its specificity. Jakl is constitutively associated with the 
ct chain, and Jak2 is bound to the /3 chain. Dimerization fthe receptor complex and tyrosine phosphorylation of both Jakl and 2 results as a consequence 
of binding IFN3,. Activation of a PTP also appears to be required to initiate this cascade [37], but its mechanism of action is not characterized. IFN3, 
treatment ofcells results in tyrosine phosphorylation of both p91 and p84 [68]. p91 may interact with the a chain through its tyrosine phosphorylated 440 
residue [72]. In a manner similar to IFNa signalling, the activated p91 is released from the membrane, translocates to the nucleus and interacts either 
directly or indirectly with a GAS/GRR element to activate transcription. The DNA-binding elements with which p91 might associate for the formation of 
a complex which binds GAS/GRR have not been characterized. 
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(which also uses Jak2 and causes tyrosine phosphorylation 
of p91-related proteins) [39,67], the function of tyrosine 
phosphatase(s) in IFN signalling remains to be elucidated. 
In addition to a membrane-associated PTPase, there ap- 
pears to be a distinct nuclear-localized PTPase activity 
which is involved in regulation of half-life of tyrosine 
phosphorylated Stats [68]. 
Identification of the components required for IFN acti- 
vation of Stat proteins has allowed experiments to be 
undertaken to understand the mechanisms by which the 
various components interact. The ligand-binding compo- 
nent of the IFNy receptor has been cloned, and reports 
have indicated that tyrosine at position 440 in the cytoplas- 
mic domain is essential for signal transduction by this 
cytokine [69,70]. Other regions such as the one adjacent to 
the transmembrane domain are also important for sig- 
nalling and for internalization of the receptor [71]. Al- 
though earlier studies rew,.aled that the IFNy receptor was 
phosphorylated on serine,/threonine residues in response 
to ligand, it was not shown until recently that the receptor 
is also rapidly tyrosine phosphorylated [63,72]. Tyrosine 
phosphorylation of the receptor is temporally associated 
with tyrosine phosphoryla~:ion f p91. Greenlund et al. [72] 
have shown that addition to cell homogenates of a syn- 
thetic peptide of the receptor containing phosphorylated 
Y440 inhibited activation of p91 as assayed by EMSA. 
Furthermore, a direct interaction between phosphorylated 
p91 and phosphorylated Y440 peptide of the receptor was 
demonstrated suggesting that p91 can directly or indirectly 
associate with the IFNT receptor after it is tyrosine phos- 
phorylated. Immunoprecipitations with antibodies to p91 in 
this laboratory have confirmed this finding (unpublished 
data). A mechanism by which the Jak kinases are recruited 
into a complex with the It,%ly receptor has been shown by 
Igarashi et al. [63]. These investigations indicated that Jakl 
is constitutively associated with the ligand binding compo- 
nent of the receptor while Jak2 is recruited into the com- 
plex in a tyrosine phosphorylated form after incubation of 
cells with IFNy [63]. Interestingly, incubation of cells with 
vanadate and hydrogen peroxide can mimic all the actions 
of IFNy, but with hydrogen peroxide and vanadate tyro- 
sine phosphorylation f p91 and Jak2 occurred more slowly 
than either phosphorylation f the receptor or Jakl [63]. 
This finding implies that activation of Jak2 is temporally 
more closely associated with tyrosine phosphorylation f
p91 than activation of Jakl. Consistent with this observa- 
tion is the fact that growth hormone which also stimulates 
tyrosine phosphorylation f p91 utilizes Jak2 but not Jakl 
for signalling [39,73-75]. However, the physiological sub- 
strates for the Jak kinase:~ still need to be determined; in
particular whether or not they directly cause tyrosine phos- 
phorylation of the Stat proteins. 
In addition to the ligand-binding chain of the IFNy 
receptor, a protein encoded on human chromosome 21 is 
also required for signalling [71]. Recently this species- 
specific accessory factor or /3-chain that does not directly 
interact with IFNT has been cloned [76,77]. The mecha- 
nism by which the accessory factor interacts with the 
ligand-binding component of the receptor, and its relation- 
ships with the Jak kinases and p91 are being determined. 
Studies recently completed by Sakatsume t al. indicate 
that the/3 chain of the receptor is associated with both the 
c~ chain and Jak2 [113]. However, the amount of Jak2 
associated with the /3 chain increases after incubation of 
cells with IFNT. One might predict hat addition of IFNT 
to cells promotes dimerization of two alpha/beta subunits 
of the receptor, followed by activation of a tyrosine phos- 
phatase/tyrosine kinase mediated signaling cascade (see 
Fig. 2). Similar results have been recently reported con- 
cerning the association of Jakl and Jak3 with different 
chains of the interleukin-2 receptor [114,115]. 
The interaction of Tyk2, Jakl, the p91 and pl13 Stat 
proteins and the IFNce receptor are less defined (see Fig. 
2). Although one component of the IFNo~ receptor was 
cloned several years ago, (IFNaR), it clearly did not bind 
IFN/3 or most types of IFNa [78]. Another subunit of the 
I FNa/ /3  receptor has recently been identified which binds 
both IFNc~ and IFN/3 and appears to be constitutively 
associated with Jakl [79]. Other data indicate that an 
antibody which inhibits IFNa signalling recognizes a sub- 
unit of the receptor that seems to be constitutively associ- 
ated with Tyk2 [80]. The protein with which this antibody 
interacts i  IFNaR, (Colamonici, personal communication), 
and is tyrosine phosphorylated as a consequence of treat- 
ment of cells with IFNa [81]. Recent evidence using a 
GST-fusion protein corresponding to the cytoplasmic do- 
main of IFNaR has demonstrated that Tyk2 binds and 
tyrosine phosphorylates this subunit of the receptor [82]. 
The binding site for Tyk2 resides within the first 50 amino 
acids adjacent to the transmembrane region of the receptor 
[82]. This region of the IFNaR receptor contains a box 1 
motif which in addition to box 2 motifs are present in the 
cytoplasmic domains of many receptors of the cytokine 
superfamily. It is now becoming apparent that box 1 and 
box 2 motifs are recognized by the Jak family of tyrosine 
kinases [83-85]. 
6. Other cytokines and growth factors which activate 
Jak kinases and Slat proteins 
The discovery that IFNs induced the expression of sets 
of early response genes by stimulating tyrosine phospho- 
rylation of SH2/SH3 domain containing transcription fac- 
tors suggested that other cytokines that interact with cell 
surface receptors which were structurally similar to the 
IFN receptors might utilize similar mechanisms. This con- 
cept became ven more attractive with reports that the Jak 
kinases were required for the actions of erythropoietin a d 
growth hormone [67,73]. EMSAs with oligonucleotides 
corresponding to enhancers that interact with IFNy acti- 
vated p91, and immunoprecipitations with p91 antiserum, 
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revealed that numerous cytokines which bind to receptors 
that either lack intrinsic tyrosine kinase activity or have 
intrinsic tyrosine kinase activity can stimulate tyrosine 
phosphorylation of p91 and DNA-binding activity 
[18,32,39,74,75,86-98]. Table 2 is a list of cytokines 
which appear to use p91 or related proteins in their sig- 
nalling cascades. In most cases where p91 is activated by a 
given mitogen there has also been shown to be Jak kinase 
involvement in the signalling cascade. In those cases where 
it has been examined it is also evident that tyrosine 
phosphorylation f p91 or related proteins is required for 
the assembly of the cytokine-induced complex which binds 
to the GRR-like enhancers. Cytokine-stimulated formation 
of complexes which bind to GRR enhancers occurs very 
rapidly, and in many cases the activated complexes 
translocate from the cytoplasm to the nucleus [39,92,98]. 
For IFN stimulation, the genes activated by p91 and 
related Stat proteins, are well characterized. In some cases 
such as IL-6-induced activation of acute phase proteins in 
the liver [99], EGF-induced activation of c-fos [32], and 
prolactin-induced induction of fl-casein gene expression 
[87], GRR-like enhancer elements have also been shown to 
be required for cytokine activation of the corresponding 
gene. However, in many instances the cellular genes that 
are presumably regulated by activation of the Stat proteins 
have not been defined. One such example is GMCSF 
which activates Jak2 and induces a Stat-like protein which 
interacts with the GRR [18]. 
Characterization f such genes will be of clear interest 
both in terms of understanding the specificity of cytokine 
signalling and in terms of obtaining more information 
about how such proteins mediate their biological actions. It 
is clear that certain complexes isolated from cytokine- 
stimulated cells bind GRR-like sequences with vastly dif- 
Table 3 
Possible mechanisms by which cytokines using the Stat/Jak pathway can 
selectively activate arly response genes 
1. Cell-specific/differentiation-dependent 
Kinases (e.g., Jak3) 
Stats (e.g., Stat4) 
Receptors (e.g., GMCSF-R) 
2. Kinase pairs 
Tyk2/Jakl: IFNot 
Jakl/Jak2: IFNT 
Jakl / Jak2/Tyk2:CNTF/OSM/LIF/ IL6 
3. Stat dimers 
homologous vs heterologous 
4. Stat tyrosine phosphorylation sites 
5. Enhancer elements 
GAS vs GRR 
6. DNA element recognition protein 
ISGF37 vs others 
Specificity by which a cytokine activates a given set of early response 
genes will probably require many of these mechanisms. 
ferent affinities [18]. This will permit some specificity with 
regard to multiple cytokines activating similar or the same 
Stat proteins. Other mechanisms that might control speci- 
ficity (see Table 3) include cell-specific expression of a 
given cytokine receptor or a given Stat protein (Stat4) or 
the selective xpression of a Jak kinase (Jak3/L-Jak in 
lymphocytes) [100-104]. The capability of a receptor to 
activate a kinase or Stat protein may be cell or develop- 
mentally regulated. It is also evident hat certain cytokines 
activate multiple Stat proteins leading to the formation of 
homodimeric or heterodimer DNA-binding complexes. 
Both EGF and IL-6 activate p91 and Stat3 or APRF, while 
IFNa activates p91 and pl13 [26,103,105] and prolactin 
activates both Statl and Stat5 [87,96]. Since these proteins 
are known to dimerize, differential activation of sets of 
Table 2 
Cytokines/growth factors which are known to active Stat or Stat-like proteins by tyrosine phosphorylation such that they can interact with GRR enhancers 
Cytokine/growth factor Tyrosine kinase STAT protein Ref. 
IFNc~ tyk2, Jakl STAT1 ot (p91), STAT1 fl (p84), STAT 2 (p113) [54-56,64,65,26,110] 
IFN3, Jakl, Jak2 STAT1 or, STAT1/3, STAT3 [54-56,63,110] 
GMCSF/IL3 Jak2 STAT5 [85,106,107,113] 
IL5 Jak2 STAT5 [109] 
EPO Jak2 STAT5 [67] 
GH Jak2 STAT1 a, STAT1 ct vaariant (?), STAT3, STATX * [73-75,113] 
PRL Jak2 STAT1 or, MGF (STAT5) [84,87,96,97,107] 
L IF/ IL6/OM/CNTF Jak 1, Jak2, tyk2 STAT3, STAT1 a (IL-6) [86,88,94,98,99,103,105,108] 
EGF Jak 1 STAT 1 c~, STAT3 [32,90-92] 
PDGF ? STAT1, STAT3 [90,110] 
IL2 Jakl, Jak3 STATX *, STAT3 [101,102,113] 
IL4 Jak 1, Jak3 IL-4-STAT [95,101,102] 
GCSF Jak 1 STAT3 [85,112] 
MCSF ? STAT1 or, STATX ~ [90] 
IL-9 Jakl, Jak2, tyk2 STAT1 o~, STATX * [111] 
IL-10 tyk2, Jakl STAT1 or, STAT3 [18,113] 
IL- 12 tyk2, Jak2 STAT4, STAT3 [ 113] 
IL-15 Jakl, Jak3 ? [113] 
In those cases where the Stat protein is not identified it is termed StatX. In the cases where it is known, the Jak kinase that is coordinately stimulated by the 
cytokine is listed. Tyrosine kinases and STAT proteins involved in cytokine/growth factor signaling. 
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Stat proteins will provide for specificity. Differential phos- 
phorylation of p91 by growth hormone in either a cell- 
specific or species-specific fashion suggests that multiple 
sites of phosphorylation besides tyrosine 701 might pro- 
vide another level of regulation [39]. Whether any of these 
other sites are tyrosine phosphorylated remains to be deter- 
mined. Finally, the DNA-.binding proteins (i.e., ISGF37) 
that may provide a scaffold on which the Stat proteins 
assemble are largely uncharacterized. These proteins could 
clearly provide yet another level of specificity to control 
gene expression. 
7. Conclusions 
A novel signalling cascade has been delineated which 
defines a mechanism by which IFNs stimulate the expres- 
sion of cellular genes. This pathway is initiated by IFN 
binding to its cell surface receptor(s), a possible clustering 
of receptors that leads to activation of tyrosine phos- 
phatase(s)/kinase(s) which ultimately results in tyrosine 
phosphorylation of one or several Stat proteins. The Jak 
kinases are important components of this cascade and are 
required for both IFNa  and IFN 7 stimulated tyrosine 
phosphorylation of p91. It remains to be determined 
whether these kinases directly phosphorylate he Stat pro- 
teins or whether they serve another function in the sig- 
nalling cascades. Although the role of tyrosine phos- 
phatase(s) in initiation of the signaling by these cytokines 
is still unknown, parallels from other cytokine signalling 
systems uggest hat these enzymes will also play critical 
roles in the transduction of signals and modulation of 
responsiveness. The discovery that numerous cytokines 
and growth factors activate Stat proteins by tyrosine phos- 
phorylation broadens the rmmber of biological responses to 
extracellular stimuli which may be regulated by this path- 
way. Now that the scope of this pathway has been defined, 
understanding how cytokines impose specificity within the 
context of the pathway and what biological responses this 
pathway regulates are problems for future investigation. 
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